Application of Cloning to the Production of Biopharmaceuticals to Treat Human and Animal Disease
Eric Overström. Professor, Tufts University, School of Veterinary Medicine
Health Care: Human & Animals
Nuclear Transfer Cloning
Advantages
- Proven methodology in several species, recent reports of success in Sheep, cattle & pigs
- Good efficiency, < ~ 98% of offspring are transgenic, demonstrates stable transgene integration & expression
- Germline transgenesis
- Less costly due to transfection/selection in vitro
Disadvantages
- Methodology not optimized in domestic animals
- Strategies for knockout & knockin constructs
|
Table 1. Development of caprine embryos reconstructed by
nuclear transfer using CFF6 transgenic fetal somatic cells
Nuclear transfer protocols |
Metaphase
II |
Telophase
II-Ca |
Telophase
II- EtOH |
Oocytes reconstructed |
138 |
92 |
55 |
Oocyte lysis (%) |
67 (48.5) |
38 (41.3) |
23 (41.8) |
Embryo cleavage (%) |
48 (34.8) |
41 (44.6) |
31 (58.4) |
Embryos transferred (%) |
37 (34) |
38 (41.3) |
27 (49.1) |
Recipients |
15 |
14 |
9 |
Ultrasound positive (%)
30 days |
9 (60) |
11 (78.6) |
5 (55.5) |
40 days |
1 (6.7) |
1 (7.1) |
0 |
60 days |
1 (6.7) |
1 (7.1) |
0 |
Term pregnancy (%) |
1 (6.7) |
1 (7.1) |
0 |
Offspring |
1 |
2 |
0 |
% of embryos transferred |
2.1 |
5.2 |
0 |
% of embryos reconstructed |
0.7 |
2.2 |
0 |
|
Table 2. rhAT expression in CFF6-1 goat milk from an
induced lactation
CFF6-1 induced
Lactation day |
hAT concentration
(g/liter) |
hAT activity
(U/ml) |
Day 3 |
4.7 |
N/D |
Day 5 |
5.8 |
20.5 |
Day 6 |
5.0 |
18.3 |
Day 7 |
4.7 |
15.6 |
Day 8 |
4.1 |
14.4 |
Day 9 |
3.7 |
14.6 |
N/D: not determined |
|
Summary
- Rational application of animal cloning to the production of
biopharmaceuticals
- Benefit to human and animal health
- Animal welfare is not compromised
- Advance fundamental understanding of mechanism that regulate normal and
abnormal cell growth
|
Email
link | Feedback | Contributed by: Boston University. Video adapted from the
Issues for the Millennium Workshop
|
|